Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T19:56:53.295Z.
Calculation as of: 2026-10-06T19:56:53.295Z.
Quote observation: 2026-10-06T19:55:22.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: fe223a2c9097866a428bc5ebda2476775355ce68fd4daeb413d6e89482dd9b46
PE RATIO
N/A
Market Cap
$1.01M
PE Ratio
N/A
TTM Avg
173046.93
3Y Avg
281427.36
5Y Avg
281427.36
Market Cap
$731546.00
PE Ratio
N/A
TTM Avg
123162.46
3Y Avg
123162.46
5Y Avg
123162.46
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| GlucoTrack, Inc. (GCTK) | $901902.00 | N/A | N/A | N/A | N/A |
| Sunshine Biopharma, Inc. (SBFM)vs › | $937294.00 | N/A | N/A | N/A | N/A |
| Bone Biologics Corporation (BBLG)vs › | $868077.00 | N/A | 0.00 | 0.00 | 0.00 |
| Bluejay Diagnostics, Inc. (BJDX)vs › | $827875.00 | N/A | N/A | N/A | N/A |
| Decoy Therapeutics Inc. (DCOY)vs › | $827210.00 | N/A | N/A | N/A | N/A |
| Ridgetech, Inc. (RDGT)vs › | $821341.00 | N/A | 0.43 | 0.43 | 0.34 |
| Aspire Biopharma Holdings, Inc. (ASBP)vs › | $1.01M | N/A | 173046.93 | 281427.36 | 281427.36 |
| China SXT Pharmaceuticals, Inc. (SXTC)vs › | $731546.00 | N/A | 123162.46 | 123162.46 | 123162.46 |
| Clearmind Medicine Inc. (CMND)vs › | $1.08M | N/A | N/A | N/A | N/A |
| CDT Equity Inc. (CDT)vs › | $716854.00 | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
